Nymox Pharmaceutical Corporation  

(Public, NASDAQ:NYMX)   Watch this stock  
Find more results for PAUL MCDONALD, ESQ�
+0.12 (5.11%)
Sep 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.30 - 2.47
52 week 0.33 - 5.55
Open 2.30
Vol / Avg. 235,785.00/1.86M
Mkt cap 89.19M
P/E     -
Div/yield     -
EPS -0.62
Shares 37.80M
Beta 1.35
Inst. own 3%

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -41697.78% -155.76%
Operating margin -41595.84% -160.19%
EBITD margin - -159.96%
Return on average assets -8795.63% -384.61%
Return on average equity - -
Employees 24 -
CDP Score - -


9900 Cavendish Blvd. Suite 306
+1-800-9369669 (Phone)
+1-514-3322227 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (BPH) which is in Phase III trials in the United States. The Company has research and development (R&D) pipeline of products in development for the treatment of conditions and diseases such as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer’s disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. Nymox has a number of diagnostic markers and technologies, including a patented platform for point-of-care testing, and has tests utilizing these technologies in the early stages of development. Nymox also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Nymox has two subsidiaries: Nymox Corporation and Serex, Inc.

Officers and directors

Paul Averback M.D. Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Erik Danielsen Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Jack Gemmell Chief Information Officer, General Counsel, Director
Age: 63
Bio & Compensation  - Reuters
Brian Doyle Senior Manager - Global Sales and Marketing
Age: 60
Bio & Compensation  - Reuters
Roger Guy M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Randall Lanham Esq. Independent Director
Age: 51
Bio & Compensation  - Reuters
Paul F. McDonald Independent Director
Age: 89
Bio & Compensation  - Reuters
David Morse Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters